Australia's most trusted
source of pharma news
Posted 14 October 2025 AM
Novo Nordisk has agreed to buy Akero Therapeutics for up to US$5.2 billion, as the race heats up in the metabolic dysfunction-associated steatohepatitis (MASH) market.
Novo will pay US$54 per share, or about US$4.7 billion up front, for San Francisco-based Akero and its lead drug efruxifermin (EFX), which Novo said has the potential to be first and best in class, with the potential to reverse liver damage, including cirrhosis. Akero shareholders will receive another US$6 per share if EFX is approved by US regulators.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.